Work

Faculty Opinions recommendation of Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Year: 2012

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.717953868.793459552

Authors: Michael Deininger, Paul La Rosée

Institutions: University of Utah, Huntsman Cancer Institute

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4247240363

Cites:

Cited by:

Related to: 10